Avid Bioservices Inc (NASDAQ:CDMO) Expected to Announce Earnings of -$0.03 Per Share

Share on StockTwits

Wall Street analysts expect that Avid Bioservices Inc (NASDAQ:CDMO) will report earnings of ($0.03) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Avid Bioservices’ earnings, with the highest EPS estimate coming in at ($0.02) and the lowest estimate coming in at ($0.03). Avid Bioservices posted earnings of ($0.06) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 50%. The firm is expected to announce its next earnings report on Monday, September 9th.

On average, analysts expect that Avid Bioservices will report full-year earnings of ($0.07) per share for the current year, with EPS estimates ranging from ($0.12) to ($0.03). For the next financial year, analysts forecast that the firm will post earnings of $0.12 per share, with EPS estimates ranging from $0.04 to $0.20. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Avid Bioservices.

Avid Bioservices (NASDAQ:CDMO) last issued its quarterly earnings results on Thursday, June 27th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $17.06 million for the quarter, compared to the consensus estimate of $15.53 million. Avid Bioservices had a negative net margin of 7.86% and a negative return on equity of 9.29%.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of General Finance from a “buy” rating to a “hold” rating in a research report on Monday, July 15th. TheStreet upgraded shares of South Jersey Industries from a “c+” rating to a “b-” rating in a research note on Tuesday, July 9th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Janney Montgomery Scott lowered shares of Unitil from a “buy” rating to a “neutral” rating and set a $59.79 price objective for the company. in a research note on Friday, June 28th. Finally, HC Wainwright set a $73.00 price objective on shares of Uniqure and gave the company a “buy” rating in a research note on Monday, July 8th. One research analyst has rated the stock with a sell rating and three have given a buy rating to the company. Avid Bioservices has an average rating of “Buy” and an average target price of $8.58.

Shares of NASDAQ CDMO traded down $0.15 during midday trading on Friday, reaching $6.11. The stock had a trading volume of 173,322 shares, compared to its average volume of 959,480. The company has a market cap of $343.02 million, a price-to-earnings ratio of -35.94 and a beta of 2.88. Avid Bioservices has a twelve month low of $3.37 and a twelve month high of $8.44. The firm has a 50 day simple moving average of $4.85.

Several large investors have recently added to or reduced their stakes in the company. AltraVue Capital LLC increased its stake in shares of Avid Bioservices by 49.7% in the 1st quarter. AltraVue Capital LLC now owns 1,975,475 shares of the biopharmaceutical company’s stock valued at $8,396,000 after acquiring an additional 655,507 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Avid Bioservices by 5.5% in the 4th quarter. Geode Capital Management LLC now owns 527,772 shares of the biopharmaceutical company’s stock valued at $2,163,000 after acquiring an additional 27,685 shares in the last quarter. Roubaix Capital LLC bought a new stake in shares of Avid Bioservices in the 1st quarter valued at $2,077,000. Legato Capital Management LLC increased its stake in shares of Avid Bioservices by 66.4% in the 1st quarter. Legato Capital Management LLC now owns 395,823 shares of the biopharmaceutical company’s stock valued at $1,682,000 after acquiring an additional 158,003 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Avid Bioservices by 128.1% in the 1st quarter. Marshall Wace LLP now owns 274,945 shares of the biopharmaceutical company’s stock valued at $1,168,000 after acquiring an additional 154,393 shares in the last quarter. Institutional investors own 38.58% of the company’s stock.

About Avid Bioservices

Avid Bioservices, Inc, a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Featured Story: Can individual investors take part in an IPO?

Get a free copy of the Zacks research report on Avid Bioservices (CDMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avid Bioservices (NASDAQ:CDMO)

Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.